Merck breaks ground on new $1 billion Biologics Center of Excellence in Delaware, US
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Metropolis Clinical Pathology will acquire and operate all laboratories and collection centers of Scientific Pathology in Agra and neighbouring towns through a slump sale transaction
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization
Subscribe To Our Newsletter & Stay Updated